The Discovery of LY293111, a Novel, Potent and Orally Active Leukotriene B4 Receptor Antagonist of the Biphenylphenol Class
| Autor: | C. R. Roman, Michael J. Sofia, Baldwin Rf, Sandra L. Cockerham, S. A. Silbaugh, K. Nelson, Larry L. Froelich, P. Marder, Floreancig Paul Edward, Stephen Richard Baker, P. W. Stengel, Jason Scott Sawyer, S. M. Spaethe, D. L. Saussy, J. H. Fleisch, W. T. Jackson, Bach Nicholas J |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Leukotriene B4
Leukotriene B4 receptor hemic and immune systems Inflammation respiratory system Pharmacology medicine.disease Inflammatory bowel disease biological factors respiratory tract diseases chemistry.chemical_compound Mediator Downregulation and upregulation chemistry medicine lipids (amino acids peptides and proteins) Granulocyte chemotaxis medicine.symptom Receptor |
| Zdroj: | Advances in Experimental Medicine and Biology ISBN: 9781461374305 |
| DOI: | 10.1007/978-1-4615-5325-0_51 |
| Popis: | Leukotriene B4 (LTB4) has been implicated as a key pro-inflammatory mediator in human diseases such as asthma, inflammatory bowel disease, psoriasis and arthritis (1). LTB4’s role in human disease is supported by the fact that via G-protein coupled receptor mediated events, this product of the 5-lipoxygenase pathway of arachidonic acid metabolism initiates granulocyte chemotaxis, aggregation, upregulation of adhesion molecules and the release of Superoxide and degradative enzymes (2). The existence of elevated concentrations of LTB4 in tissues or interstitial fluids of patients with inflammatory diseases also supports the role of LTB4 as a pro-inflammatory mediator (1). However, the presence of LTB4 associated with the clinical manifestations of these inflammatory diseases only indirectly implicates it as a major player in inflammatory processes. The delineation of LTB4’s role in inflammation requires the development of potent and selective LTB4 receptor antagonists. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|